Thus, the effect of TRPML2 silencing or TRPML2 activation using different doses of ML2-SA1 agonist for 24 h was evaluated in GBM cells treated with Doxorubicin (DOX: 1–50 μM). The gene discussed is STAG1; the disease is glioblastoma.